HomeCompareSGIOY vs GIS

SGIOY vs GIS: Dividend Comparison 2026

SGIOY yields 1.82% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGIOY wins by $562.9K in total portfolio value· pulled ahead in Year 6
10 years
SGIOY
SGIOY
● Live price
1.82%
Share price
$11.09
Annual div
$0.20
5Y div CAGR
70.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$641.7K
Annual income
$420,841.59
Full SGIOY calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — SGIOY vs GIS

📍 SGIOY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGIOYGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGIOY + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGIOY pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGIOY
Annual income on $10K today (after 15% tax)
$154.36/yr
After 10yr DRIP, annual income (after tax)
$357,715.35/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, SGIOY beats the other by $343,935.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGIOY + GIS for your $10,000?

SGIOY: 50%GIS: 50%
100% GIS50/50100% SGIOY
Portfolio after 10yr
$360.3K
Annual income
$218,526.43/yr
Blended yield
60.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

SGIOY
No analyst data
Altman Z
10.6
Piotroski
4/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGIOY buys
0
GIS buys
0
No recent congressional trades found for SGIOY or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGIOYGIS
Forward yield1.82%6.53%
Annual dividend / share$0.20$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.4%22.8%
Portfolio after 10y$641.7K$78.8K
Annual income after 10y$420,841.59$16,211.26
Total dividends collected$599.7K$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SGIOY vs GIS ($10,000, DRIP)

YearSGIOY PortfolioSGIOY Income/yrGIS PortfolioGIS Income/yrGap
1$11,009$309.44$11,502$801.73$493.00GIS
2$12,323$542.53$13,365$1,058.29$1.0KGIS
3$14,152$967.05$15,712$1,411.34$1.6KGIS
4$16,912$1,768.72$18,716$1,904.17$1.8KGIS
5$21,461$3,365.93$22,629$2,603.16$1.2KGIS
6← crossover$29,766$6,802.41$27,826$3,612.21+$1.9KSGIOY
7$46,875$15,024.95$34,871$5,097.54+$12.0KSGIOY
8$87,836$37,680.36$44,643$7,331.52+$43.2KSGIOY
9$206,429$112,444.03$58,541$10,772.15+$147.9KSGIOY
10$641,720$420,841.59$78,850$16,211.26+$562.9KSGIOY

SGIOY vs GIS: Complete Analysis 2026

SGIOYStock

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Full SGIOY Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this SGIOY vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGIOY vs SCHDSGIOY vs JEPISGIOY vs OSGIOY vs KOSGIOY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.